Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience Walbert led recent acquisition of Horizon Therapeutics by Amgen for $28.3 billion THOUSAND OAKS, Calif., November 19, 2024 – Latigo Biotherapeutics (“Latigo”), a clinical-stage biotechnology company developing…